v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating Activities:    
Net loss $ (28,755) $ (7,198)
Adjustments to reconcile net loss to net cash used in operating activities:    
Non-cash lease expense 679 765
Depreciation and amortization 983 997
Stock-based compensation 3,146 3,056
Provision for uncollectible accounts 2,847 1,418
Unrealized exchange gain (loss) and other (206) 594
Provision for inventory 1,216 2,228
Change in fair value of warrant liabilities (12,800) (17,024)
Change in fair value of derivative liabilities   (1,895)
Change in fair value of debt 3,615 (18,090)
Change in fair value of Revenue Interest Financing and PIPE Conversion Option 9,090 4,771
Change in fair value of earn-out liabilities (1,059) (22,900)
Change in fair value of RTW Share Obligation 370  
Interest paid on debt recorded at fair value (2,410) (3,098)
Non-cash interest expense   1,464
Loss on extinguishment of debt 660 8,713
Debt issuance costs associated with debt recorded at fair value   1,357
Issuance costs associated with warrants recorded at fair value 1,502 942
Changes in operating assets and liabilities:    
Accounts receivable 844 8,977
Inventory (486) 543
Prepaid expenses, other current and long-term assets 800 913
Lease liabilities (796) (836)
Accounts payable (3,141) (3,924)
Accrued expenses and other current liabilities (5,045) (4,073)
Net cash used in operating activities (28,946) (42,300)
Investing Activities:    
Purchases of property and equipment   (611)
Net cash used in investing activities   (611)
Financing Activities:    
Proceeds from issue of convertible notes   48,000
Proceeds from private offerings, net of issuance costs 4,597 2,592
Proceeds from public offerings, net of issuance costs 13,578 17,660
Payment of debt issuance costs   (1,357)
Repayment of Fortress Term Loan   (47,720)
Proceeds from option and warrant exercises   26
Proceeds from equity line financing 795 1,007
Net cash provided by financing activities 18,970 20,208
Net decrease in cash and cash equivalents and restricted cash (9,976) (22,703)
Cash and cash equivalents and restricted cash at beginning of period 15,718 38,421
Cash and cash equivalents and restricted cash at end of period 5,742 15,718
Supplemental disclosure of cash flow information    
Cash paid for interest   2,672
Supplemental cash flow information on non-cash investing and financing activities    
Deferred financing costs in accounts payable and accrued expenses 115 323
Change in fair value of RTW Convertible Notes through OCI 5,330 (4,700)
Change in fair value of Revenue Interest Financing through OCI 8,180 (4,370)
Conversion of Series A Preferred Stock into Common Stock   (979)
Common stock issued for conversion of convertible notes $ (6,585)  
Exercise of PIPE Conversion Option   $ (547)